Skip to main content
SpringerLink
Log in

Determination of Fc-Mediated Antibody-Effector Functions by Chromium Release Assay

  • Protocol
Antibody Engineering

Part of the book series: Springer Protocols Handbooks ((SPH))

  • 5103 Accesses

Monoclonal antibodies (mAbs) can exert their biological functions by a large variety of mechanisms and have therefore become a major part in the treatment of diseases like viral infections and cancer. For the clinical efficacy of many mAbs Fc-mediated effector functions like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) play an essential role. This protocol describes a simple method to test whether a monoclonal antibody is able to induce ADCC or CDC using a chromium release assay.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bhakdi S, Tranum-Jensen J (1991) Complement lysis: a hole is a hole. Immunol Today 9:318–320

    Article  Google Scholar 

  • Brunner KT, Mauel J, Cerottini JC, Chapuis B (1968) Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 2:181–196

    Google Scholar 

  • Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 3:754–758

    Article  Google Scholar 

  • Clark MR (1997) IgG effector mechanisms. Chem Immunol 65:88–110

    Article  PubMed  CAS  Google Scholar 

  • Clynes R (2006) Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am 3:585–612

    Article  Google Scholar 

  • Clynes R, Ravetch JV (1995) Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 1:21–26

    Article  Google Scholar 

  • Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 4:443–446

    Google Scholar 

  • Cooper NR (1985) The classical complement pathway: activation and regulation of the first complement component. Adv Immunol 37:151–216

    Article  PubMed  CAS  Google Scholar 

  • Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 13:4664–4669

    Article  Google Scholar 

  • Glennie MJ, van de Winkel JG (2003) Renaissance of cancer therapeutic antibodies. Drug Discov 11:503–510 Today

    Google Scholar 

  • Goldsby RA, Kindt TJ, Osborne BA, Kuby J (2003) Immunology, Fifth Edition, WH Freeman and Company, New York, 1–551

    Google Scholar 

  • Greenwood J, Clark M, Waldmann H (1993) Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 5:1098–1104

    Article  Google Scholar 

  • Iannello A, Ahmad A (2005) Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 4:487–499

    Article  Google Scholar 

  • Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 5787:670–673

    Article  Google Scholar 

  • Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 11:4005–4010

    Article  Google Scholar 

  • Morgan A, Jones ND, Nesbitt AM, Chaplin L, Bodmer MW, Emtage JS (1995) The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. Immunology 2:319–324

    Google Scholar 

  • Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 5753:1510–1512

    Article  Google Scholar 

  • Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 1:19–28

    Article  Google Scholar 

  • Otz (2008) New approaches for an antibody-based treatment of CD20+ lymphoid neoplasia. tobias-lib.ub.uni-tuebingen.de/volltexte/2008/3316/index.html

  • Presta LG (2006) Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 5–6:640–656

    Article  Google Scholar 

  • Presta LG, Shields RL, Namenuk AK, Hong K, Meng YG (2002) Engineering therapeutic antibodies for improved function. Biochem Soc Trans 4:487–490

    Google Scholar 

  • Raju TS (2008) Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 4:471–478

    Article  Google Scholar 

  • Sanz L, Blanco B, Alvarez-Vallina L (2004) Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol 2:85–91

    Article  Google Scholar 

  • Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 9:6591–6604

    Article  Google Scholar 

  • Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 30:26733–26740

    Article  Google Scholar 

  • Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 5:3466–3473

    Google Scholar 

  • Strome SE, Sausville EA, Mann D (2007) A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 9:1084–1095

    Article  Google Scholar 

  • Waldmann TA (2003) Immunotherapy: past, present and future. Nat Med 3:269–277

    Article  Google Scholar 

  • Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940–3947

    Article  PubMed  CAS  Google Scholar 

  • Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 23:4717–4724

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Stuttgart, Institute for Cell Biology and Immunology, Allmandring 31, Stuttgart, Germany

    Tina Otz

Authors
  1. Tina Otz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tina Otz .

Editor information

Editors and Affiliations

  1. (Biomedical Engineering) Institut für Zellbiologie und Immunologie, Universität Stuttgart, Allmandring 31, 70569, Stuttgart, Germany

    Roland Kontermann

  2. Technische Universität Braunschweig, Institut für Biochemie und Biotechnologie, Spielmannstraße 7, 38106, Braunschweig, Germany

    Stefan Dübel

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag

About this protocol

Cite this protocol

Otz, T. (2010). Determination of Fc-Mediated Antibody-Effector Functions by Chromium Release Assay. In: Kontermann, R., Dübel, S. (eds) Antibody Engineering. Springer Protocols Handbooks. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01144-3_49

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01144-3_49

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01143-6

  • Online ISBN: 978-3-642-01144-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation